Business Context and Reporting Period
This Form 6-K filing by GSK plc, dated December 11, 2025, reports a corporate action regarding a block listing application. The filing does not cover a financial reporting period but rather announces an administrative event effective December 12, 2025.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a notice of share admission and contains no financial performance data.
Material Changes
The material change reported is the application to the Financial Conduct Authority and the London Stock Exchange for the admission of 250,000 Ordinary Shares of 31½p each to the Official List. These shares are reserved under the GlaxoSmithKline plc Share Save Plan 2022 and will rank pari passu with existing Ordinary Shares upon issuance.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risks, contingencies, or unusual items. The only forward-looking statement is the expectation that admission to the Official List will be effective on December 12, 2025.
Investor Verification Checklist
- Verify the effective date of the share admission (expected December 12, 2025).
- Confirm the total number of shares admitted (250,000) and their nominal value (31½p each).
- Check the London Stock Exchange Official List for the formal admission of these shares.
- Review the GlaxoSmithKline plc Share Save Plan 2022 terms to understand the source of these reserved shares.